癌症和心血管疾病是美国的前两大死因。在过去几十年中，新型疗法减缓了癌症的死亡率，然而由于癌症治疗的毒性作用，心脏衰竭的发生率却上升了。这种关系的机制尚不明确，因此妥善治疗那些易发生心脏衰竭的患者至关重要。目前，我们依靠早期炎症和血管生成的生物标志物来检测心脏毒性反应，以防止其不可逆转。识别这些生物标志物使得医疗专业人员能够减少癌症治疗的不良效果。血管生成和炎症对心脏和血管有着系统性的影响，癌症治疗后尤为明显。在心脏肿瘤学领域，近年来对于性别和种族差异在心脏毒性中的重要性以及这些差异对疾病结果的影响有了较多关注，然而不同人群心脏毒性的差异数据仍然很少。本文将讨论当前由癌症治疗引起的血管生成和炎症标志物与心血管健康差异的关系。版权所有 © 2023，Elsevier Inc. 发表。

Cancers and cardiovascular diseases are the top two causes of death in the United States. Over the past decades, novel therapies have slowed the cancer mortality rate, yet cardiac failures have risen due to the toxicity of cancer treatments. The mechanisms behind this relationship are poorly understood and it is crucial that we properly treat patients at risk of developing cardiac failure in response to cancer treatments. Currently, we rely on early-stage biomarkers of inflammation and angiogenesis to detect cardiotoxicity before it becomes irreversible. Identification of such biomarkers allows healthcare professionals to decrease the adverse effects of cancer therapies. Angiogenesis and inflammation have a systemic influence on the heart and vasculature following cancer therapy. In the field of cardio-oncology, there has been a recent emphasis on gender and racial disparities in cardiotoxicity and the impact of these disparities on disease outcomes, but there is a scarcity of data on how cardiotoxicity varies across diverse populations. Here, we will discuss how current markers of angiogenesis and inflammation induced by cancer therapy are related to disparities in cardiovascular health.Copyright © 2023. Published by Elsevier Inc.